Business Description
Xenon Pharmaceuticals Inc
NAICS : 325412
SIC : 3741
ISIN : CA98420N1050
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 67.11 | |||||
Equity-to-Asset | 0.97 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.05 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -57.2 | |||||
3-Year EPS without NRI Growth Rate | -50.2 | |||||
3-Year FCF Growth Rate | -15.4 | |||||
3-Year Book Growth Rate | 38.1 |
Momentum Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 35.42 | |||||
9-Day RSI | 39.66 | |||||
14-Day RSI | 40.32 | |||||
6-1 Month Momentum % | -14 | |||||
12-1 Month Momentum % | -0.58 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 31.82 | |||||
Quick Ratio | 31.82 | |||||
Cash Ratio | 31.48 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -29.1 | |||||
Shareholder Yield % | -0.06 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -24.91 | |||||
ROA % | -23.81 | |||||
ROIC % | -108.71 | |||||
ROC (Joel Greenblatt) % | -1188.06 | |||||
ROCE % | -29.21 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 3.07 | |||||
Price-to-Tangible-Book | 3.07 | |||||
EV-to-EBIT | -9.09 | |||||
EV-to-EBITDA | -9.25 | |||||
EV-to-Forward-Revenue | 603.85 | |||||
EV-to-FCF | -12.92 | |||||
Price-to-Projected-FCF | 256.92 | |||||
Price-to-Net-Current-Asset-Value | 4.03 | |||||
Price-to-Net-Cash | 4.08 | |||||
Earnings Yield (Greenblatt) % | -11 | |||||
FCF Yield % | -5.78 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Xenon Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -2.506 | ||
Beta | 0 | ||
Volatility % | 44.04 | ||
14-Day RSI | 40.32 | ||
14-Day ATR (€) | 0.624429 | ||
20-Day SMA (€) | 34.2 | ||
12-1 Month Momentum % | -0.58 | ||
52-Week Range (€) | 25.8 - 46 | ||
Shares Outstanding (Mil) | 75.47 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Xenon Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Xenon Pharmaceuticals Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Xenon Pharmaceuticals Inc Frequently Asked Questions
What is Xenon Pharmaceuticals Inc(STU:XP0)'s stock price today?
When is next earnings date of Xenon Pharmaceuticals Inc(STU:XP0)?
Does Xenon Pharmaceuticals Inc(STU:XP0) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |